Objective
to report the 2-year clinical outcomes of TAVR versus surgery in patients at low surgical risk
Study
multicentre randomised trial
Population
patients with aortic valve stenosis at low surgical risk (STS-PROM) of <4%
Endpoints
death from any cause, all stroke or cardiovascular rehospitalisation at 2 years
Conclusion
all-cause death, all stroke and rehospitalisation remained significantly lower at 2 years in patients with aortic stenosis at low surgical risk with TAVR treatment compared to surgical treatment
Leon et al. J Am Coll Cardiol. 2021;77:1149-61
